According to Zhitong Finance App, Peger Biopharmaceutical-B (02565.HK) issued an announcement. On November 2, 2026 (after the trading period), the company entered into a placement agreement with the exclusive placement agent. According to this, the company has already agreed to use the exclusive placement agent to place a total of 26.813 million shares to no less than six undertakers at a price of HK$2.985 per share on a best-effort basis. Such placement shares will be issued by the company under general authorization in accordance with the terms and conditions set out in the placement agreement.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.